The Impact of Preclinical Irreproducibility on Drug Development

The development of novel therapeutics depends and builds upon the validity and reproducibility of previously published data and findings. Yet irreproducibility is pervasive in preclinical life science research and can be traced to cumulative errors or flaws in several areas, including reference mate...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2015-01, Vol.97 (1), p.16-18
Main Authors: Freedman, LP, Gibson, MC
Format: Article
Language:English
Subjects:
Data Collection - methods
Data Collection - standards
Drug Design
Drug Evaluation, Preclinical - methods
Humans
Reproducibility of Results
Research Design - standards
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of novel therapeutics depends and builds upon the validity and reproducibility of previously published data and findings. Yet irreproducibility is pervasive in preclinical life science research and can be traced to cumulative errors or flaws in several areas, including reference materials, study design, laboratory protocols, and data collection and analysis. The expanded development and use of consensus‐based standards and well‐documented best practices is needed to both enhance reproducibility and drive therapeutic innovations.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.9